 CAMBRIDGE, Mass., Feb. 9, 2022 PRNewswire -- Theseus Pharmaceuticals, Inc. NASDAQ: THRX Theseus, a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that Tim Clackson, Ph.D. 